Synergistic polymorphisms of β1 and α2C-adrenergic receptors and the influence on left ventricular ejection fraction response to β-blocker therapy in heart failure
Authors:
- 1 April 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 17 (4) , 277-282
Abstract
Objectives The Arg389Gly polymorphism (Arg389Gly) in the β1-adrenergic receptor gene (ADRB1) has been associated with improvement in left-ventricular remodeling with β-blocker treatment. One study of risk for heart failure suggested a synergistic effect of ADRB1 Arg389Gly with the insertion/deletion polymorphism in the α2C-adrenergic receptor gene (ADRA2C). We tested whether the ADRA2C insertion/deletion polymorphism was associated with β-blocker response in heart failure, either alone or in combination with the ADRB1Arg389Gly polymorphism. Methods Fifty-four β-blocker naive heart failure patients underwent echocardiography before and after 5–6 months of metoprolol CR/XL therapy. Multivariant linear regression modeling was performed to assess the impact of genotypes and other variables on changes in left-ventricular function in response to metoprolol therapy. Results Deletion carriers had a significantly greater negative chronotropic response. Predictors of the end of study ejection fraction were baseline ejection fraction, deletion carrier status and Arg389Arg genotype. Patients with Arg389Arg/Del-carrier status showed the greatest ejection fraction increase with metoprolol CR/XL. Adjusting for baseline ejection fraction, final S-metoprolol plasma concentration and race, final ejection fraction in patients with this genotype combination was significantly higher than all other genotype combination groups. Conclusion ADRB1 and ADRA2C polymorphisms synergistically influence the ejection fraction response to β-blocker therapy of heart failure patients.Keywords
This publication has 24 references indexed in Scilit:
- The Polymorphonuclear Leukocyte and the Abdominal Aortic AneurysmCirculation, 2005
- -Adrenoceptor polymorphismsNaunyn-Schmiedeberg's Archives of Pharmacology, 2003
- Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practiceActa Physiologica Scandinavica, 2003
- Differential Effects of β-Blockers in Patients With Heart FailureCirculation, 2000
- Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart FailureJAMA, 2000
- Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failureThe American Journal of Cardiology, 1999
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999
- Left Ventricular Remodeling With Carvedilol in Patients With Congestive Heart Failure Due to Ischemic Heart Disease fn1fn1This study was funded by a grant from SmithKline Beecham; however, the study was initiated, conducted, analyzed and reported by the Australia–New Zealand Heart Failure Research Collaborative Group independently of the sponsor. The Clinical Trials Research Unit is supported by a programme grant from the Health Research Council of New Zealand.JACC, 1997
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockadeJACC, 1995